---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336767"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2026-08-06T11:40:21+00:00"
generated_at: "2026-08-06T11:45:14.868948+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen DSMB recommends advancing PGN-EDODM1 to 12.5 mg/kg; Q2 net loss $17.8M

## Summary
- DSMB recommends advancing FREEDOM2-DM1 to 12.5 mg/kg highest dose cohort; no protocol changes.
- DSMB also approves OLE dose escalation from 5 mg/kg to 10 mg/kg; 6 of 8 from 5 mg/kg cohort enrolled in OLE.
- 10 mg/kg cohort fully enrolled, 7 of 8 completed dosing; data expected November 2026.
- Q2 2026 net loss $17.8M ($0.26 per share) vs $23.1M ($0.70) in Q2 2025; R&D expenses $12.5M.
- Cash $117.2M as of June 30, 2026; sufficient into Q4 2027.

## SEC filing metadata
- accession: 0001193125-26-336767
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2026-08-06T11:40:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/0001193125-26-336767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/pepg-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336767
- JSON: https://secwatch.observer/filing/0001193125-26-336767.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.